At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 751 enrolled
Drug / intervention
LY900014 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
In Brief
A Phase 3 clinical trial evaluating LY900014, Insulin Lispro, and 2 other interventions for Type 1 Diabetes Mellitus. Completed, enrolled 751 participants across 111 sites in 18 countries.
Detailed Summary
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) in children and adolescents with type 1 diabetes (T1D).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes Mellitus
CountriesAustria, Brazil, China, Czechia, Denmark, France, Germany, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russia, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartApr 2019
Primary CompletionJul 2021
TodayJul 2026
First PostedNov 14, 2018
Enrollment StartApr 7, 2019
Primary CompletionJul 2, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.6 years ago
Interventions
LY900014drug
Administered SC
Insulin Lisprodrug
Administered SC
Insulin Glarginedrug
Administered SC
Insulin Degludecdrug
Administered SC